GLP-1s, Pregnancy, and Breastfeeding: What the Label Actually Says

This is a topic where a single oversimplified rule — "no GLP-1s if you might get pregnant or are nursing" — gets repeated constantly and is not quite right. The pregnancy guidance is genuinely simple. The breastfeeding guidance is not one-size-fits-all, and the difference between the injection and the tablet formulation of semaglutide matters more than most people realize.

Pregnancy: the guidance is straightforward

Discontinue a GLP-1 at least two months before a planned pregnancy. Both the Wegovy and Zepbound labels give this instruction because of the drugs' long half-life — roughly a week — which means the medication stays in your system well after the last dose³⁴. Wegovy's label is explicit: "discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide"³. This is not a suggestion; it is the labeled guidance, and it is why family planning is a question a real prescriber should ask before starting you on a GLP-1 — one more reason a genuine intake, not a rubber-stamp form, matters (see our provider checklist).

There is not yet enough controlled human data to call these drugs safe or unsafe in pregnancy with certainty. Both manufacturers maintain a pregnancy exposure registry that tracks outcomes in people who become pregnant while on the drug, and a 2025 review in the American Journal of Obstetrics and Gynecology summarizing the available evidence found no consistent signal of major birth-defect risk in the pregnancy exposures reported to date — while also noting the data remain limited and encouraging continued registry enrollment². The honest summary: the labeled instruction is to stop before pregnancy, and if a pregnancy happens on the drug, the existing (still-limited) data are not alarming, but this is a conversation for your OB, not a DIY call.

Breastfeeding: this is where "just don't" is actually wrong for some formulations

Here is the distinction that gets lost. **Wegovy tablets** — the oral semaglutide tablet formulation of Wegovy — contain an absorption-enhancing excipient called SNAC. A clinical lactation study of the oral tablet found semaglutide itself below the limit of detection in breast milk, but SNAC and its metabolites were present, and because infants may clear SNAC more slowly than adults, the label advises that breastfeeding is not recommended during treatment with WEGOVY TABLETS specifically³.

**WEGOVY injection is a different formulation and carries no such warning.** The injection does not contain SNAC. The label states there are no data on subcutaneously administered semaglutide in human milk, but frames the decision as a standard benefit-risk conversation between a nursing mother and her clinician — not a "do not breastfeed" instruction³. In other words: the reason breastfeeding is discouraged on the tablet is a specific excipient in that formulation, not semaglutide itself — and the injectable form of the same drug does not carry that same exclusion.

**Tirzepatide (Zepbound) has real transfer data, and it is reassuring.** A single-dose clinical lactation study measured tirzepatide in breast milk after a 5 mg subcutaneous dose in 11 lactating adults: the drug was undetectable in 164 of 171 milk samples collected, and in the handful where it was detected, the cumulative amount over 28 days came to less than 0.02% of the maternal dose⁴. A separate 2024 study measuring semaglutide transfer during breastfeeding similarly found minimal drug transfer into human milk¹. Both labels still frame the ultimate decision as one to make with a clinician, weighing the benefits of breastfeeding against the mother's clinical need for the medication — but the actual transfer data for both injectable formulations is reassuring, not alarming.

The one-sentence summary

Stop any GLP-1 at least two months before a planned pregnancy. If you are breastfeeding and considering an injectable semaglutide or tirzepatide, the labeled concern is specific to the semaglutide *tablet's* excipient — not a blanket exclusion on the drug class — and the actual milk-transfer data for the injections is minimal. This is exactly the kind of nuance a real prescriber should walk you through rather than you inferring it from a warning label alone.

Where this fits into your bigger decision

Family planning is one of several factors a genuine intake should surface before you start — alongside the thyroid cancer boxed warning and the other exclusions covered in who qualifies for a GLP-1, and who shouldn't take one. It is also a real formulary question: not every provider offers both the injection and the tablet, and the choice between them may matter more to a nursing parent than to anyone else. Compare formulary breadth across providers in the ranked reviews, scored under our Verdict Score methodology.

This is editorial information, not medical advice. Pregnancy and breastfeeding decisions involving any medication should be made with your OB/GYN or prescribing clinician.